Neurontin Bulk Supply May Limit Generic Uptake, Pfizer Says
Executive Summary
Neurontin generics will have to overcome limitations in the bulk drug supply in addition to Pfizer's patent defenses, Pfizer CEO Henry McKinnell told a Jan. 22 earnings conference call
You may also be interested in...
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25
Orange Book Listings For Unapproved Uses May Be OK, Appeals Court Says
Congress should revisit Waxman/Hatch to clarify whether the statute is intended to restrict the scope of patent protection to only approved uses of a drug, U.S. Federal Circuit Judge Richard Linn said